French and Spanish CROs combine on expertise to address cross-country clinical trials.
Henko Partners, an Iberian private equity firm, has announced its investment in PopsiCube and MissionTEC, two French CROs. PopsiCube operates in various therapeutic areas including oncology, rare diseases, and cardiovascular disease, and its subsidiary MissionTEC has developed strategies needed for decentralized clinical trials.
Along with BioClever, a CRO in Spain with strong expertise in biometrics and a Henko Partners investment since July 2022, the equity firm is building a pan-European CRO that will offer an expanded range of clinical trials services cross-country, in addition to servicing national markets. The new European CRO will manage early to late phase studies and including decentralized clinical trials.
The founders and current management team of PopsiCube will continue to lead the company. Henko will provide operating support alongside capital to accelerate the business plan.
Reference: Henko Partners invests in PopsiCube and MissionTEC to create a European CRO. Madrid, May 4, 2023.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.